These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29371619)

  • 21. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.
    Kapoor N; Vanjak I; Rozzelle J; Berges A; Chan W; Yin G; Tran C; Sato AK; Steiner AR; Pham TP; Birkett AJ; Long CA; Fairman J; Miura K
    Biochemistry; 2018 Feb; 57(5):516-519. PubMed ID: 29323879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
    Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming.
    Yusuf Y; Yoshii T; Iyori M; Yoshida K; Mizukami H; Fukumoto S; Yamamoto DS; Alam A; Emran TB; Amelia F; Islam A; Otsuka H; Takashima E; Tsuboi T; Yoshida S
    Front Immunol; 2019; 10():730. PubMed ID: 31024558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen.
    Mlambo G; Kumar N; Yoshida S
    Vaccine; 2010 Oct; 28(43):7025-9. PubMed ID: 20709008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.
    Bai J; Liu F; Yang F; Zhao Y; Jia X; Thongpoon S; Roobsoog W; Sattabongkot J; Zheng L; Cui Z; Zheng W; Cui L; Cao Y
    Vaccine; 2023 Jan; 41(2):555-563. PubMed ID: 36503858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
    Goodman AL; Blagborough AM; Biswas S; Wu Y; Hill AV; Sinden RE; Draper SJ
    PLoS One; 2011; 6(12):e29428. PubMed ID: 22216279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.
    Barr PJ; Green KM; Gibson HL; Bathurst IC; Quakyi IA; Kaslow DC
    J Exp Med; 1991 Nov; 174(5):1203-8. PubMed ID: 1940798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Pb51 in Plasmodium berghei as a malaria vaccine candidate targeting both asexual erythrocytic proliferation and transmission.
    Wang J; Zheng W; Liu F; Wang Y; He Y; Zheng L; Fan Q; Luo E; Cao Y; Cui L
    Malar J; 2017 Nov; 16(1):458. PubMed ID: 29132428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
    Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND; Raz AA; Sani JJ
    Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936155
    [No Abstract]   [Full Text] [Related]  

  • 34. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
    Mizutani M; Fukumoto S; Soubeiga AP; Soga A; Iyori M; Yoshida S
    Malar J; 2016 Apr; 15(1):251. PubMed ID: 27129682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein.
    Persson C; Oliveira GA; Sultan AA; Bhanot P; Nussenzweig V; Nardin E
    J Immunol; 2002 Dec; 169(12):6681-5. PubMed ID: 12471098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.
    Espinosa DA; Vega-Rodriguez J; Flores-Garcia Y; Noe AR; Muñoz C; Coleman R; Bruck T; Haney K; Stevens A; Retallack D; Allen J; Vedvick TS; Fox CB; Reed SG; Howard RF; Salman AM; Janse CJ; Khan SM; Zavala F; Gutierrez GM
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity.
    Farrance CE; Chichester JA; Musiychuk K; Shamloul M; Rhee A; Manceva SD; Jones RM; Mamedov T; Sharma S; Mett V; Streatfield SJ; Roeffen W; van de Vegte-Bolmer M; Sauerwein RW; Wu Y; Muratova O; Miller L; Duffy P; Sinden R; Yusibov V
    Hum Vaccin; 2011; 7 Suppl():191-8. PubMed ID: 21266847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice.
    Datta D; Bansal GP; Kumar R; Ellefsen B; Hannaman D; Kumar N
    Clin Vaccine Immunol; 2015 Sep; 22(9):1013-9. PubMed ID: 26135972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.